Science News
from research organizations

Duke Scientist Reports Advances In Gene Therapy For Heart Failure

November 10, 1998
Duke University Medical Center
Scientists are one step closer to making gene therapy for heart failure a reality, scientists from Duke University Medical Center report.

DALLAS -- Scientists are one step closer to making gene therapy for heart failure a reality, scientists from Duke University Medical Center reported Sunday.

Molecular biologist Walter J. Koch and his colleagues said in a report prepared for the 71st scientific sessions of the American Heart Association that they have for the first time delivered therapeutic genes throughout a rabbit's heart and have shown that the genes can increase heart function.

The animal experiments are a crucial step in developing a genetic treatment for congestive heart failure, a debilitating and deadly condition in which heart muscle loses its ability to stretch and contract, usually due to clogged arteries caused by coronary artery disease. People with congestive heart failure often experience fatigue, weakness, and an inability to carry out routine daily tasks. Right now, there is no effective means to reverse heart failure, only to treat symptoms.

According to the American Heart Association, about 400,000 new cases are recorded every year in the United States. Death rates from congestive heart failure tripled between 1974 and 1994, making it the leading cause of hospitalization among people 65 and older and costing more than $10 billion a year.

Koch, an associate professor of experimental surgery, and his colleagues have been working for several years to find ways to efficiently deliver genes to the heart to boost heart function.

Early experiments focused on identifying the molecular players that are responsible for efficient pumping action in the heart and showing which ones aren't doing their jobs in failing hearts. Using mouse models and sophisticated genetic techniques, the Duke scientists showed that two key proteins in heart cells work together to regulate heart function.

In diseased hearts, the body releases the hormone norepinephrine, the "fight-or-flight" hormone, directly into the heart, causing it to work up to five times harder than normal. Norepinephrine binds to molecules called beta adrenergic receptors (BARs) present on heart cells. This stimulation initially allows the heart to increase the power of its contractions, but in heart failure it quickly becomes self-defeating: the receptors become desensitized, meaning they no longer are able to respond to hormone stimulation. Desensitization is caused by a second molecule called B-adrenergic receptor kinase (BARK), which in healthy hearts helps restore heart contractions to normal after norepinephrine stimulation. Studies subsequently showed that BARK is elevated in failing human heart tissue.

In 1994, Duke researchers showed that mice genetically altered to produce excess beta adrenergic receptors (bARs) have supercharged hearts that beat faster and stronger than a normal mouse's heart. In 1997, the researchers inserted a gene that encodes the bAR into an adenovirus, the same virus that causes the common cold. When Koch and his colleagues allowed the virus to infect isolated failing rabbit heart cells, the bAR gene made up to 15 times the normal amount found in rabbit cells and restored normal heart signaling.

"Our studies have shown that a malfunctioning beta adrenergic receptor system leads directly to heart failure," Koch said. "By contrast, boosting levels of beta adrenergic receptors or inhibiting BARK can reverse heart failure in our mouse genetic models. Now, we are beginning to see the same result when we deliver these genes to rabbits."

The researchers used the results of the mouse studies to design their latest gene therapy experiments in rabbits. They increased the number of bARs by infusing a common cold virus genetically engineered to contain the bAR gene into a living rabbit's heart and allowing it to spread throughout the coronary arteries. Then they measured the ability of the heart to pump. Animals that received extra copies of bAR, which is equivalent to 10 times the normal number of bARs on heart cells, had significantly increased ability to pump, demonstrated by a 20 percent increase in the force of the heart's contraction.

The key to the researchers' success, Koch said, was using a new surgical method to ensure that the adenovirus spread throughout the heart. They injected the virus into the left ventricle of live rabbits while the aorta was clamped for a few seconds. This allowed the virus enough time to spread through all the coronary vessels. Clamping the aorta is sometimes used in human heart surgery, Koch said, making this gene delivery method feasible.

In previous experiments, the researchers used a catheter similar to the ones used in opening blocked arteries in people to inject the virus into the coronary arteries, the arteries that feed the heart, in live rabbits. Using this method, Koch and his colleagues demonstrated that they could get genes into heart muscle and that the heart cells made the appropriate protein product, but only in a limited area of heart muscle.

The researchers are continuing experiments with a new generation of gene transfer agents such as the cold virus. But, he said, better gene therapy vectors need to be developed before gene therapy for heart failure in people becomes a practical option.

Story Source:

Materials provided by Duke University Medical Center. Note: Content may be edited for style and length.

Cite This Page:

Duke University Medical Center. "Duke Scientist Reports Advances In Gene Therapy For Heart Failure." ScienceDaily. ScienceDaily, 10 November 1998. <>.
Duke University Medical Center. (1998, November 10). Duke Scientist Reports Advances In Gene Therapy For Heart Failure. ScienceDaily. Retrieved May 22, 2017 from
Duke University Medical Center. "Duke Scientist Reports Advances In Gene Therapy For Heart Failure." ScienceDaily. (accessed May 22, 2017).